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ABSTRACT 
Transurothelial drug delivery continues to be an attractive treatment option for a range of 
urological conditions, however dosing regimens remain largely empirical. Recently, intravesical 
delivery of the non-steroidal anti-inflammatory ketorolac has been shown to significantly reduce 
ureteral stent-related pain. While this latest development provides an opportunity for advancing 
in the management of stent-related pain, its translation into effective patient management will 
undoubtedly benefit from an understanding of the rate and extent of delivery of ketorolac into the 
bladder wall. Using an ex vivo porcine model, we evaluate the urothelial permeability and 
bladder wall distribution of ketorolac. The subsequent application of a pharmacokinetic (PK) 
model enables prediction of concentrations achieved in vivo. 
Ketorolac was applied to the urothelium and a transurothelial permeability coefficient 
(Kp) calculated. Relative drug distribution into the bladder wall after 90 minutes was determined. 
Ketorolac was able to permeate the urothelium (Kp = 2.63 x 10
-6
 cm s
-1
) and after 90 minutes 
average concentrations of 400, 141 and 21 µg g
-1
 were achieved in the urothelium, lamina 
propria and detrusor respectively. An average concentration of 87 µg g
-1
 was achieved across the 
whole bladder wall. PK simulations (STELLA
®
) were then carried out, using ex vivo values for 
Kp and muscle/saline partition coefficient (providing an estimation of vascular clearance), to 
predict 90 minutes in vivo ketorolac tissue concentrations. When dilution of the drug solution 
with urine and vascular clearance were taken into account, a reduced ketorolac concentration of 
37 µg g
-1
 across the whole bladder wall was predicted.  
These studies reveal crucial information about the urothelium's permeability to agents such as 
ketorolac and the concentrations achievable in the bladder wall. It would appear that levels of 
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ketorolac delivered to the bladder wall intravesically would be sufficient to provide an anti-
inflammatory effect. The combination of such ex vivo data and PK modelling provides an insight 
into the likelihood of achieving clinically relevant concentrations of drug following intravesical 
administration.  
Key words: Intravesical; Ketorolac; Pharmacokinetics; Urothelium; Stent 
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1. Introduction 
 
Intravesical drug delivery (IDD), the most common form of transurothelial drug delivery, takes 
advantage of the bladder’s unique anatomy to allow the prolonged exposure of high 
concentrations of drug to the bladder’s luminal surface, whilst minimising systemic absorption. 
IDD therefore overcomes the shortcomings of systemic therapy, which is often ineffective due to 
poor bladder bioavailability and unwanted adverse effects 
1,2
. 
However, the effectiveness of IDD is limited by several intrinsic properties of the bladder. A 
specialised, highly impermeable epithelial layer, known as the urothelium, lines the luminal 
surface. The urothelium is an exceptional barrier with reported transepithelial resistances ranging 
from 10,000 to 75,000 Ω cm2 3; these represent some of the highest values of all epithelia 
measured to date 
4
. The urothelium is the primary barrier to the movement of molecules from the 
urine into the blood and will limit the extent to which drugs can permeate into the bladder wall 
1
. 
Additionally urine flows into the bladder at a constant rate (1 ml min-1) 5 diluting the 
concentration of instilled drug and the need to regularly void the bladder means any drug load 
will subsequently be lost, reducing exposure time to the bladder wall. Whilst IDD has 
historically been used as a method for delivering drugs locally to the lower urinary tract, it is 
inevitable that future developments will seek to improve both controllability and sustainability of 
therapeutic strategies by incorporating drugs into devices such as ureteral stents 
6,7
.  
Despite having been used for a number of decades, intravesical dosing regimens remain largely 
empirical. This subject has received some attention with investigations into the bladder wall 
permeation of common intravesical solutions 8–10, as well as the effect of permeation enhancers 
such as chitosan and dimethyl sulfoxide 11–13. Recently it has been shown that enhanced bladder 
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wall uptake can be achieved using nanoparticle delivery systems for superficial bladder cancer 
14–18. 
Despite this, many questions remain unanswered about the ability of different drugs to 
permeate across the urothelium and ultimately the viability of delivering drugs in this manner. In 
vivo data from IDD studies is limited, due to the difficulty in obtaining bladder tissue 
concentrations in human and animal subjects, and therefore dosing regimens are typically based 
on perceived clinical benefits. Although qualitative end points are clinically useful, quantitative 
data on urothelial permeability and bladder tissue distribution is far more important when 
predicting the usefulness of new local drug delivery approaches. Research of this kind has clear 
clinical translation and is key if we are to maximise the potential of delivering drugs locally to 
the urinary tract.  
The primary aim of the current study was to improve our knowledge of IDD by probing the 
permeability of the bladder wall in an ex vivo setting. To this end we have investigated ketorolac, 
a non-steroidal anti-inflammatory drug (NSAID) commonly used in urological practice in the 
US, as an exemplar. We describe an ex vivo approach for estimating local tissue drug 
concentrations achievable after IDD, which can be used not only to predict the usefulness of 
prospective therapies but also to optimise existing dosing regimens. 
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 2.  Experimental section 
 
2.1.  Bladder preparation 
 
Porcine bladders, from pigs weighing 70-90 kg, were obtained fresh from a local abattoir 
within five minutes of excision and transported in ice-cold oxygenated Krebs buffer back to the 
laboratory. Bladders were filled and drained with 37 °C saline to remove any residual urine. 
Using a scalpel, excess perivesical fat was trimmed away and a single straight-line incision made 
along the length of the bladder exposing the right and left lateral sides. The bladder was cut into 
2 cm
2
 sections from the lateral sides and dome area and loaded into glass Franz-type diffusion 
cells (Figure 1) (Permegear Inc, Hellertown, PA, USA) with the urothelium facing upwards. 
Care was taken to avoid contact with the urothelial surface and a metal clamp was used to secure 
the tissue between the donor and receiver chambers of the in the Franz-type cells. The receptor 
compartment was filled with oxygenated Krebs buffer and equilibrated at 37 °C for 30 min with 
a micro stirrer bar providing continuous stirring. A solution of the drug was pipetted into the 
donor chamber which was covered with a glass disc to prevent evaporative loss. The sampling 
arm was capped and the Franz-type cells placed in to a thermostatically controlled water bath, 
maintained at 37 °C, on top of a submersible magnetic stirrer plate. 
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Fig 1. Schematic of a Franz-type diffusion cell loaded with porcine bladder tissue  
 
2.2. Confirmation of tissue viability 
 
2.2.1. Investigating paracellular marker permeability 
 
The viability of the bladder tissue over 5 h was evaluated in an assay investigating the co-
permeation of propranolol hydrochloride (≥ 99%, Acros Organics, Geel, Belgium) and sodium 
fluorescein (≥ 95%, Sigma-Aldrich Ltd, Dorset, England) across the urothelium and lamina 
propria. A 500 l aliquot of a saline solution of 1 mM propranolol hydrochloride and 0.1 mM 
sodium fluorescein was added to the donor chamber of the Franz-type cell. At fixed time points 
(0.5, 1.5, 3.5 and 5 h), the contents of the receptor and donor chambers were collected and the 
tissue sample removed.  
Prior to removal with a cork borer, the area of tissue in contact with the drug was subjected to 
three saline rinses (1 ml each rinse) to remove any adsorbed drug and the urothelium and lamina 
propria carefully separated from the underlying detrusor muscle by cutting along the natural 
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plane of division with a scalpel. Tissue sections were weighed and drug recovered by repeated 
extraction in methanol.  
Propranolol hydrochloride was analysed using HPLC (Kromasil C18 column, 5 m, 250 mm x 
4.6 mm i.d column, Supelco Inc). The mobile phase consisted of 70 % acetonitrile : 30 % sodium 
dodecyl sulfate (10 mM), disodium hydrogen phosphate (10 mM) adjusted to pH 2.3 with 
phosphoric acid. UV detection was set at 290 nm. The injection volume was 20 l and a flow 
rate of 1 ml min
-1
 was used.  
Sodium fluorescein was analysed using a FLUOstar OPTIMA platereader (BMG Labtech 
GmbH, Ortenburg, Germany) set at an excitation wavelength of 485 nm and emission 
wavelength of 520 nm.  
To ensure accurate separation of the bladder mucosa from the detrusor muscle, histology was 
performed. The urothelium and lamina propria were removed from one half of a bladder section, 
with the other half remaining as full thickness bladder tissue. Tissue samples were fixed to cork 
mounts with optimal cutting temperature medium (OCT) (Tissue-Tek™, CRYO-OCT 
Compound, Fisher Scientific UK Ltd, Leicestershire, England) and snap frozen in a dry ice-
hexane bath. Samples were sectioned at 10 µm using a cryostat (Leica CM3050 S, Leica 
Microsystems, Buckinghamshire, England). Sections were then stained with haematoxylin-eosin 
(H&E) for examination by light microscopy. 
 
2.2.2. Transepithelial electrical resistance 
 
The integrity of urothelial, paracellular tight junctions was investigated by measuring any change 
in the transepithelial electrical resistance (TEER) across the bladder mucosa over time. The 
 9 
urothelium and lamina propria was carefully removed and a 1 x 1 cm
2
 section mounted into an 
Ussing chamber (NaviCyte vertical multichannel Ussing chambers, Warner Instruments, 
Hamden, CT, USA). The mucosal chamber was filled with 4 mls of either normal saline or 
ketorolac 1.1 mg ml
-1
 in saline, whilst the serosal chamber was filled with 4 mls of oxygenated 
Krebs buffer. The Ussing chambers were maintained at 37 °C and after a 10 minute equilibration 
period, TEER across the mucosa measured at 15 minute intervals. The TEER value at time zero 
was taken to be the baseline reading, from which the percentage change from baseline TEER was 
calculated. To account for any basal resistance of the setup, Ussing chambers were prepared as 
above but without any bladder mucosa loaded. TEER values were then subtracted from tissue 
readings and the net electrical resistance of the mucosa multiplied by the apparent exposed tissue 
area (0.12 cm
2
) of the Ussing chamber to yield the TEER. Percentage change from baseline 
TEER was compared for the saline and ketorolac groups with statistical analysis performed using 
GraphPad Prism version 6.0c (GraphPad Software, Inc, La Jolla, CA, USA). TEER was 
measured using a multi-channel voltage–current clamp (EC-800 single channel, Warner 
Instruments, Hamden, CT, USA). The Ussing chambers were equipped with two pairs of Ag / 
AgCl electrodes, for measuring potential difference (V) and for passing current (I). The 
experiments were performed under open circuit conditions, whereby the current was set to zero 
and the natural transepithelial potential differende could be observed. Electrical readings were 
recorded every 15 minutes. Electrical resistance was determined according to Ohm’s law (R = V 
/ I).  
 
 
2.2.3. Scanning electron microscopy 
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To investigate the possibility of urothelial cell desquamation or morphological changes to 
urothelial surface, bladder tissue was examined by scanning electron microscopy (SEM). 
Bladder sections were loaded into Franz-type diffusion cells and 500l of normal saline, 
ketorolac 1.1 mg ml
-1
 in saline or protamine sulfate 10 mg ml
-1
 in saline added to the donor 
chamber. After 90 minutes the contents of the donor chambers were removed, the urothelial 
surface subjected to three saline rinses (1 ml each rinse) and the tissue sample removed. An 
additional sample, which was fixed at the abattoir approximately 10 minutes after slaughter, was 
examined as a control. Sections of tissue (2 x 2 cm
2
) were carefully cut without touching the 
urothelial surface and fixed in a solution of 4% formaldehyde and 0.2% glutaraldehyde in 0.1 M 
phosphate buffer for 24 hours at room temperature. Following a wash in distilled water ( 2 x 60 
min), tissue samples were dehydrated in isopropyl alcohol solutions of increasing concentrations 
(50–100%) before undergoing chemical drying in 100% hexamethyldisilazane. Samples were 
then sputter-coated with gold in an Emscope sputter coater (Emscope, Ashford, Kent, UK) 
before examination at 5 kV with a scanning electron microscopy (Jeol JSM 840A, Tokyo, 
Japan). Images were acquired with an ADDA 2 image grabber and processed using Scandium 
analysis software (Soft Imaging System GmbH, Münster, Germany). 
 
2.3. Evaluation of the delivery of ketorolac to the bladder wall 
 
2.3.1. Permeation of ketorolac across the urothelium  
 
Franz-type cells were assembled as described (2.1) and a 0.5 ml aliquot of a 1.1 mg ml
-1
 
ketorolac solution (normal saline) (Ketorolac tris salt, ≥ 99%, Sigma-Aldrich Company Ltd, 
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Dorset, England) was applied to the donor chamber. At fixed time points (1, 2, 3.5 and 5 h), the 
contents of the receptor and donor chambers were collected and the tissue sample removed. The 
tissue was rinsed with saline and the ketorolac extracted as described in 2.2. 
Ketorolac was analysed using HPLC (Kromasil C18 column, 5 m, 25 mm x 4.6 mm i.d 
column, Supelco Inc). The mobile phase consisted of 60 % 0.02 M phosphate buffer (adjusted to 
pH 3.5 with phosphoric acid) : 40 % acetonitrile, with UV detection at 315 nm. The injection 
volume was 20 l and a flow rate of 1 ml min-1 was used. 
 
2.3.2. Distribution of ketorolac into the bladder wall 
 
Franz-type cells were assembled as described (2.1) and a 500 l aliquot of a 1.1 mg ml-1 
ketorolac solution (normal saline) was applied to the donor chamber. After 90 min the Franz-
type cells were dismantled and the urothelial surface rinsed with saline following collection of 
the donor and receiver compartments. The area of drug contact was isolated, fixed in OCT and 
tissue samples sectioned using a cryostat as described (2.2.1). Care was taken to ensure OCT was 
only present on the serosal side of the tissue.  Samples were serially sectioned parallel to the 
urothelial surface at 50 μm thickness and sections collected in pre-weighed 1.5 ml eppendorf 
tubes. Tissue sections between 0 and 200 μm (urothelium) were collected individually for 
analysis, whilst five tissue sections between 200 and 1200 μm (lamina propria) and ten tissue 
sections between 1200 and 3200 (detrusor muscle) were collected and pooled for analysis. For 
pooled samples, tissue depths were expressed as the midpoint depth of the sections. Tissue 
sections were then weighed, extracted in 500 l methanol for 24 hours and drug quantified using 
HPLC as described (2.3.1). Average tissue concentrations achieved in the urothelium, lamina 
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propria, detrusor muscle and whole bladder wall were calculated by dividing the total amount of 
drug recovered by the total weight of tissue in that layer.  
 
2.4. Determination of the muscle to saline partition coefficient for ketorolac  
 
Detrusor muscle was isolated by removing the urothelium and lamina propria as described 
(2.2.1) and then turning the tissue over to excise the adventitia and serosa in the same manner. 
Muscle sections were then weighed, placed in a capped 10 ml glass collecting vial and 
submerged in 3 ml of 11 μg ml-1 ketorolac solution (normal saline). The drug solution was 
sampled at pre-defined time points (1, 1.5, 2, 4 and 6 h) and at 6 h the muscle section was 
removed and ketorolac extracted to allow the muscle/saline partition coefficient to be calculated. 
 
2.5. Pharmacokinetic modelling 
 
STELLA
®
 (Structural Thinking Experimental Learning Laboratory with Animation, Isee 
systems inc, New Hampshire, USA) is a computer program that facilitates the mapping, 
modelling, simulation and communication of dynamic processes 
19
. For this study STELLA
®
 
was used to create a PK model of intravesical drug delivery. STELLA® version 10.0.2 software 
was used to create a basic pharmacokinetic model of IDD allowing the incorporation of vascular 
drug clearance from the bladder wall and dilution of intravesically instilled drug by urine into 
our ex vivo experiments. This model assumes the lamina propria and detrusor muscle to be one 
compartment with vascular clearance taking place throughout. This assumption is based on the 
relative small size of the lamina propria, the presence of intermittent smooth muscle strands in 
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the lamina propria (muscularis mucosae) 
20
 and the presence of capillary networks in both layers 
21,22
.  
  
 14 
3. Results 
 
3.1. Confirmation of tissue viability 
 
Sodium fluorescein and propranolol hydrochloride are recognised paracellular and 
transcellular markers respectively 
23,24
. In this study the two compounds have been used to 
evaluate the integrity of the urothelial barrier over 5 h. The results presented in Figure 2A show 
the amount permeated through the urothelium and lamina propria for each marker over time 
calculated by summing the amount of drug extracted from the detrusor muscle and any drug 
recovered from the receptor compartment. Permeability coefficients (Kp) were calculated to be 
5.1 x 10
-6
 cm s
-1
 and 1.3 x 10
-6
 cm s
-1
 for propranolol hydrochloride and sodium fluorescein 
respectively. Figure 2B shows the successful removal of the urothelium and lamina propria 
(U/LP) leaving the underlying detrusor muscle (M).  
Deviation from baseline TEER across the bladder mucosa was investigated after the 
application of saline and ketorolac to the urothelium (Supplementary data S.1). All mucosa 
samples used had baseline TEER values greater than 500 .cm2, indicative of tight epithelia 25. 
TEER values decreased marginally with time and after 90 min mucosa exposed to saline and 
ketorolac exhibited 82 and 85 % of baseline TEER respectively. At the end of the experiment 
(2.5 h) values were 77 and 78 % of baseline TEER for saline and ketorolac respectively. There 
was no significant difference in TEER reduction between samples exposed to saline or ketorolac 
at any timepoint (p = 0.511 for 1.5 h timepoint. Significance calculated using two-tailed, 
unpaired, student’s t-test). 
The integrity of the ex vivo bladder urothelium was analysed by SEM (Figure 3). Tissue 
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exposed to saline and ketorolac displayed normal surface morphology as evidenced by the 
polygonal-shaped umbrella cells (A and B). There is evidence of intact tight junctions between 
adjacent cells, an example of which has been traced for clarity (green dashed line). The urothelial 
surface morphology of tissue exposed to saline or ketorolac did not differ from the control 
sample fixed on-site at the abattoir within 5 minutes of excision (supplementary data S.2). Tissue 
exposed to protamine sulfate (C) exhibited a different morphology with widened tight junctions, 
cell lysis (circled red) and apparent shedding of the umbrella cell’s apical membrane (red arrow).  
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Fig 2. (A) Permeation profile of 0.1 mM sodium fluorescein and 1 mM propranolol 
hydrochloride across porcine urothelium and lamina propria, Permeability coefficients (Kp, cm s
-
1
) were calculated by normalising the flux (J, g cm-2 s-1) to the dosing concentration (A). (n = 4 
± SD, 2 bladders randomised across sampling times). (B) Photomicrograph of a haematoxylin 
and eosin stained bladder section with the urothelium and lamina propria excised from half the 
section (400x). U/LP – urothelium and lamina propria, M – detrusor muscle. 
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Figure 3. Scanning electron micrographs of ex vivo porcine bladder tissue loaded into Franz-type 
diffusion cells and treated with saline (A), 1.1 mg ml
-1 
ketorolac (B) and 10 mg ml
-1
 protamine 
sulfate for 90 mins (C). Images show that after exposure to saline and ketorolac the urothelium 
remains intact (A and B). After exposure to protamine there is a marked loss of barrier integrity 
(C). (For additional SEM micrographs see supplementary data S.2)  
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3.2 Permeation of Ketorolac through the bladder wall 
 
In this experiment, unlike in 3.1, there was no separation of the urothelium and lamina propria 
from the detrusor muscle. This was a case of experimental improvement; studies in our lab 
showed that after multiple saline washes of the urothelial surface any remaining adsorbed drug 
was within error of the amounts calculated from tissue extraction. Therefore any drug extracted 
after the saline rinse is considered to have permeated the urothelium making the separation step 
unnecessary. Drug that had permeated the urothelium was calculated by summing drug extracted 
from the tissue and any drug recovered from the receptor compartment. Drug was only present in 
receiver samples for the 5 hr time point, constituting 0.2% of the applied dose. The profile in 
Figure 4A shows that after 5 h approximately 60 g cm-2 of ketorolac had permeated into the 
bladder wall. A Kp value of 2.63 x 10
-6
 cm s
-1
 was calculated for ketorolac across the urothelium. 
Mass balance studies showed that on average 93% of the applied dose was recovered per sample 
(Figure 4B).   
The distribution of ketorolac into the bladder wall after 90 min is shown in Figure 5. As 
expected drug concentrations declined with tissue depth with average concentrations of 400, 141 
and 21 µg g
-1
 achieved in the urothelium, lamina propria and detrusor muscle respectively. After 
90 min the average concentration in the whole bladder wall was calculated to be 87 µg g
-1
.  
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Fig 4. (A) Permeation profile of 1.1 mg ml
-1 
ketorolac across porcine bladder urothelium, 
Permeability coefficients (Kp, cm s
-1
) were calculated by normalising the flux (J, g cm-2 s-1) to 
the dosing concentration. (B) Mass balance analysis of the recovery of ketorolac from the Franz-
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type cell setup per sampling timepoint. (n = 4 ± SD, 2 bladders randomised across sampling 
times). 
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Fig 5. (A) Concentration-depth profile of ketorolac into porcine bladder wall after 90 min. For 
pooled samples, tissue depths were expressed as the midpoint depth of the sections. IC50 
represents the top-end value reported at COX-1 and COX-2 for ketorolac
26
. (B) Corresponding 
average ketorolac concentrations achieved in the urothelium (0-200m), lamina propria (200-
1250m), detrusor muscle (1250-3200m) and whole bladder wall (0-3200m) after 90 min (B). 
(n = 5 bladders ± SD). 
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3.3. Determination of the muscle/saline partition coefficient for ketorolac 
 
The concentration of ketorolac solution decreased until equilibrium is established at 
approximately 2 h (Figure 6A). At equilibrium (2-6 h) the ketorolac concentration was 9.5 µg ml
-
1 
and 6.4 µg ml
-1 
in the solution and detrusor muscle respectively (Figure 6B), thus giving a 
muscle/saline partition coefficient of 0.67. 
 
 
 
 
 
 
 
 
 
Fig 6. Partition coefficient experiment, showing the concentration of ketorolac in the bathing 
solution over 6 h (A) and comparison of the concentration of ketorolac in the bathing solution 
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with that in the detrusor muscle at equilibrium (B). (n = 10 ± SD, 1 bladder randomised across 
sampling times).   
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3.4. Pharmacokinetic modelling 
 
Using STELLA
®
, a pharmacokinetic model was created to simulate IDD (Figure 7). The 
model combines differential equations derived from basic pharmacokinetic theory with constants 
derived from experimentally calculated values (such as the drug’s Kp and muscle/blood partition 
coefficient) to provide a dynamic overview of the factors affecting IDD. Simulations used 
Euler’s method of integration with calculations applied every 0.25 seconds. The model was used 
to approximate for drug clearance from the bladder wall and the dilution effect of urine, 
processes that are otherwise absent in our static ex vivo experiments. Total urine production by 
the kidneys was assumed to be 1 ml min
-1
. Although this rate can vary, 1 ml min
-1
 is a well 
accepted value for adults 
27–29
. For full explanations of the equations / constants utilised in the 
PK model see supplementary data S.3. 
Figure 8 was generated by the model and shows the effects of clearance and dilution on the 
intravesical delivery process. The constant production of urine will dilute the concentration of 
drug in the bladder lumen (Fig 8A and B), which is the driving force for the passive diffusion of 
drug into the bladder wall. The model predicts that this gives rise to a 42% decrease in the drug 
concentration achieved in the bladder wall after 90 minutes (Fig 8C). Vascular clearance 
continually carries drug from the bladder tissue into the systemic circulation. The model suggests 
that this will result in a 24% decrease in bladder wall drug concentration after 90 minutes (Fig 
8D). The combination of the dilution effect of the urine and the clearance of drug from the 
bladder wall results in a predicted 58% decrease in the overall drug concentration achieved in the 
bladder wall at 90 minutes (Fig 8E).  
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Fig 7. Overview of the computer-based pharmacokinetic model designed using STELLA
®
.
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Fig 8. The results of our pharmacokinetic model predictions. For each figure, residual urine = 0 
ml, intravesical instillation = 55mg of ketorolac in 50mls saline, KPerm = 2.63 x 10
-06
 cm s
-1
, KElim 
= 8.08 x 10
-05
 s
-1
 (see S.3 for calculation), bladder wall mass = 1g, exposed surface area of 
urothelium = 1.32 cm
2
 and urine production rate = 1 ml min
-1
. At 90 minutes post intravesical 
instillation; urine production by the kidneys has increased the bladder volume from 50 to 140 
mls (A), resulting in a 64% decrease in the final drug concentration in the bladder lumen (B) 
(note the luminal drug concentration decreases even in the absence of urine production (1100 to 
1069 g ml-1) due to transurothelial permeation, which is taking place in both scenarios). 
Subsequently, this results in a 42% decrease in the drug concentration achieved in the bladder 
wall (C).  In the absence of urine production, but including an estimate for vascular clearance, a 
24% decrease in the drug concentration achieved in the bladder wall is predicted (D). The 
combination of urine dilution and clearance gives rise to a 58% decrease in the bladder wall drug 
concentration (E). 
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4. Discussion 
 
The aim of this study was to investigate the transurothelial delivery and bladder wall 
distribution of the NSAID ketorolac using an ex vivo porcine model. 
Porcine bladder tissue was a natural choice for our ex vivo experiments owing to the long 
history of pigs being used as animal models in urology. A number of studies have reported the 
physiology of the urinary tract of pigs to be similar to that of humans 
30–32
.  
It was important to ensure that the urothelium remained viable throughout the course of our 
experiments. A viable barrier would be expected to not only prevent significant permeation, but 
also differentiate between the transcellular and paracellular movement of molecules. The 
integrity of the urothelium was evaluated over 6.5 h using two established markers of 
permeation. Sodium fluorescein was employed as a paracellular marker whilst propranolol 
hydrochloride was used to represent permeation via the transcellular route. Over 6.5 h the 
permeation rate of both molecules was constant, indicative of little change in the tissue’s 
behaviour. Furthermore the calculated Kp values (Figure 2A) were distinct and, although there 
are no directly comparable figures available in the literature, in the same range as those reported 
for other molecules permeating the urothelium 
33
.  
TEER is an established method of investigating the paracellular permeability of the urothelium 
34–37
. By assessing the resistance across bladder mucosa we can evaluate the maintenance of the 
tight junctions between umbrella cells crucial to the barrier function of the urothelium. Porcine 
bladder mucosa exposed to saline (control) or ketorolac showed no significant difference in 
TEER reduction at any timepoint (2.1 and supplementary data S.1). The marginal decrease in 
TEER with time for all samples was within range of what can be expected for ex vivo 
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experiments such as this. In agreement with our observations, it has recently been shown using 
TEER that excised, ex vivo bladder tissue loaded in side-by-side diffusion cells retains 
transurothelial barrier function for at least 6 hours 
37
. 
In addition to alterations in tight junction permeability, an increase in paracellular permeability 
may result from epithelial cell loss 
34
. Using SEM we microscopically examined the superficial 
surface of the ex vivo porcine bladder tissue to elucidate urothelial integrity (2.2.3). After 90 
minutes the application of saline or ketorolac to bladder tissue loaded in the Franz-cell setup had 
no significant effect on the morphology of the urothelium (Fig 3 and supplementary data S.2). 
Scallop-shaped, superficial umbrella cells with intact tight junctions were evident and closely 
resembled that reported by others 
38–40
. Protamine sulfate in a concentration of 10 mg ml
-1
 has 
been shown to cause immediate umbrella cell sloughing accompanied by a significant decrease 
in TEER across the urothelium 
38
. For this reason protamine sulfate was used as negative control. 
The urothelium of bladder tissue exposed to protamine sulfate showed a significant loss of 
integrity with widespread umbrella cell lysis and subsequent exposure of the underlying 
intermediate cells (Fig 3C and supplementary data S.2).  
In combination, the results of investigations into paracellular permeation, TEER and SEM 
analysis suggest that the ex vivo porcine bladder tissue was appropriate for use in our studies. 
Recently, Beiko et al 
41
 evaluated the safety and effectiveness of localised, intravesical 
ketorolac (1.1 mg ml
-1
) to reduce ureteral stent-related pain. They found a significant reduction 
in stent-related pain 1 h after stent placement when compared to the control group. While this 
latest development provides an opportunity for advancing in the management of stent-related 
pain, its translation into effective patient management will undoubtedly benefit from an 
understanding of the rate and extent of delivery of ketorolac into the bladder wall. By gathering 
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information regarding the barrier properties of the urothelium and investigating, in quantitative 
terms, ketorolac delivery, we can begin to make predictions about the viability of delivering 
ketorolac intravesically and the bladder tissue concentrations necessary to bring about a 
therapeutic effect. We chose therefore to use a 1.1 mg ml
-1
 ketorolac solution in our ex vivo 
studies. According to the mean urination time reported, ketorolac would have been voided from 
the bladder after approximately 90 min explaining our use of this endpoint.   
Although the exact aetiology of stent-related pain is unclear, a common theory is that the distal 
curl of the ureteral stent irritates the urothelium resulting in spasm, aperistalsis and pain 
42
. 
Prostaglandins have been shown to produce contractions of isolated detrusor muscle in vitro 
43
 
and their synthesis can be initiated by detrusor muscle stretch and bladder urothelial damage 
44
. 
Blocking prostaglandin synthesis with indomethacin, a non-selective cyclooxygenase (COX) 
inhibitor, has recently been shown to decrease acetylcholine-mediated autonomic contractions in 
the isolated bladder 
45
. In addition, afferent C-fibres terminating in the urothelium and lamina 
propria are known to respond to prostaglandins released (from cells in the urothelium and lamina 
propria) in response to injury 
46
; suggesting the possibility that, by inhibiting mediators released 
from urothelial and lamina propria cells, intravesically delivered NSAIDs (such as ketorolac) 
may provide pain relief in part via modulation of sensory pathways. 
 The NSAID ketorolac nonselectively inhibits cyclooxygenase 1 and 2 (COX-1 and COX-2), 
the enzymes responsible for the production of prostaglandins and has been shown to inhibit 
ureteral contractility in vitro 
47
. It follows that by reducing inflammation and spasm, ketorolac 
should be beneficial in reducing stent-related pain thus explaining its choice by Beiko et al 
41
. 
Our permeation study (Figure 4A) shows that ketorolac is capable of permeating across the 
urothelium (Kp value = 2.63 x 10
-6
 cm s
-1
). The production of prostaglandins within the bladder 
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wall is well established with synthesis occurring not only in the detrusor muscle but also from 
within the urothelium and lamina propria 
43,48–50
, both of these regions can therefore be taken to 
be targets for the IDD of ketorolac. In agreement with others who have performed concentration-
depth studies on ex vivo porcine bladder, our distribution study (Figure 5) shows a linear 
decrease in drug concentration over the urothelium, followed by an exponential decrease in 
concentration over the lamina propria and detrusor muscle 
12,14
. After 90 min the total 
concentration in these target regions was 87 µg g
-1
.  
To address the absence of dilution by urine and vascular drug clearance from the bladder wall 
in our experiments, a PK bladder model was built using STELLA
®
. By visualising complex 
differential equations, STELLA
® 
enables users to build dynamic models of highly complex 
systems. The models can be used to investigate the contribution of different variables on the 
system as a whole. STELLA
®
 is therefore suited to pharmacokinetic (PK) modelling and has 
been used to develop a range of models including PK profiles for enteric tablets 
51
, the enhanced 
oral bioavailability of lipid formulations 
52
 and ocular permeation following the topical 
application of drugs 
53,54
. 
Only two intravesical PK models have previously been reported for investigating the effect of 
physiological and pharmacological parameters upon drug concentrations achieved in the bladder 
wall 
55,56
. The most well known of these was developed in the early nineties by Wientjes et al 
who used computer-based PK simulations to suggest the optimum dosing strategy for the 
intravesical delivery of mitomycin C 
55
. In contrast to these previous approaches, the user-
friendly model described in this study delivers a high resolution PK prediction based on the 
simultaneous solution of multiple interconnected differential equations. In addition, the speed 
and flexibility of STELLA
® 
allows the user to rapidly generate a range of PK simulations by 
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varying determinants such as the rate of urine production, residual urine volume or 
transurothelial permeation rate. STELLA’s® graphical capabilities allow simulations be explored 
in real time allowing a better and faster understanding of the dynamic processes underlying the 
intravesical drug delivery process. This capability will be valuable clinicians wishing to explore 
intravesical dosing regimens for different drugs in the future.  We are the first group to 
demonstrate this kind of real-time, intravesical PK simulations. A muscle/saline partition 
coefficient was determined to provide an estimate for the in vivo muscle/blood partition 
coefficient for ketorolac. Using this, in conjunction with the calculated Kp value, the PK model 
was designed to incorporate both the predicted effects of drug clearance and dilution by urine 
into our permeation data. Vascular clearance and dilution by urine have independent effects on 
the concentrations of drug achieved in the bladder wall (Fig 8). Importantly the dilution effect 
was shown to be the more significant of the two, resulting in a predicted 42% decrease in bladder 
wall drug concentration at 90 minutes (Fig 8C). Our pharmacokinetic model suggests that, due to 
dilution and vascular clearance, in vivo drug concentrations may be 58 % lower than the tissue 
concentrations determined in the ex vivo studies (Figure 5E). Applying this correction factor to 
the results from the ex vivo distribution study (Figure 5) predicts a 90 minute bladder wall drug 
concentration of 37 µg g
-1
.  
 The reported potency of ketorolac, in terms of IC50 values, varies widely with top end 
values of 31.5 and 60.5 μM for COX-1 and COX-2 respectively 26. Taking the clearance/dilution 
corrected value of 37 µg g
-1
 and making the assumption that 1 g of bladder tissue has a volume 
of ~ 1 cm
3
, a ketorolac tissue concentration of 98.3 µM would be achieved 90 minutes after 
application of 1.1 mg ml
-1
 drug solution. This equates to a ketorolac concentration of at least 
three times the IC50 for COX-1 and one and a half times the IC50 for COX-2 at the site of action, 
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suggesting that levels of ketorolac in the bladder wall would be pharmacodynamically 
appropriate to provide an anti-inflammatory effect. 
In conclusion, using an ex vivo porcine approach we have studied the transurothelial 
permeation of ketorolac and quantitatively investigated its delivery into the different layers of the 
bladder wall. Using ketorolac as an example, we have shown how fundamental studies such as 
these can be used to predict the viability of delivering drugs intravesically in vivo. It would 
appear that the levels of ketorolac delivered to the bladder wall following IDD are 
pharmacodynamically appropriate to provide an anti-inflammatory effect. In practice intravesical 
dosing is largely guided by clinical outcome, with little information available on target drug 
concentrations. Investigations such as those described here yield quantitative ex vivo data and 
predictive in vivo information that can be used to rationally design new transurothelial drug 
delivery strategies and optimise existing intravesical drug regimens. 
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